ABION Attends Bio Japan... "Sharing Pipeline Achievements and Discussing LO"

ABION announced on the 8th that it will attend BIO JAPAN, held from the 9th to the 11th of this month at the National Convention Hall in Pacifico Yokohama, Japan.

Hosted by the Japan Bioindustry Association, BIO JAPAN is a global pharmaceutical and bio conference that has been held since 1986. Approximately 1,500 companies worldwide participate in various fields including pharmaceuticals and bio, digital healthcare, regenerative medicine, and health functional foods. Through last year’s event, about 20,000 partnering meetings were conducted, establishing it as Asia’s leading pharmaceutical and bio exhibition.

At BIO JAPAN, ABION plans to share the achievements of its key pipelines, including △non-small cell lung cancer treatment Vabametkib (ABN401) △antibody-cytokine conjugation platform technology ABN202 △Claudin 3 (CLDN3) targeting monoclonal antibody ABN501. The company will also discuss joint research and licensing-out (LO) with global companies to devise strategies for maximizing corporate value.

A company representative stated, “We will promote Vabametkib, which is being developed as the best-in-class new drug within our group, to the world and seek various collaboration opportunities with companies attending the event. In particular, we will strengthen our network through meetings with potential partners in Japan and discover new partners.”

This content was produced with the assistance of AI translation services.